Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MK-767. Kyorin/Banyu/Merck.

Anna C Calkin1, Merlin C Thomas, Mark E Cooper

  • 1Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, St Kilda Rd Central, Melbourne, Victoria 8008, Australia. anna.calkin@baker.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|June 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial Alterations and CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection.

Kidney international·2026
Same author

EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach.

Science advances·2026
Same author

Effects of empagliflozin on cardiac function and cardiorespiratory fitness in people with type 2 diabetes: a randomised controlled trial.

Cardiovascular diabetology. Endocrinology reports·2026
Same author

Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease.

Diabetes·2026
Same author

Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study.

Cardiovascular diabetology·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

MK-767 is an investigational drug targeting peroxisome proliferator-activated receptor (PPAR) alpha and gamma. It is being developed for diabetes treatment and is currently in Phase III clinical trials.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Peroxisome proliferator-activated receptors (PPARs) play crucial roles in regulating glucose and lipid metabolism.
  • Dysregulation of PPARs is implicated in the pathogenesis of type 2 diabetes.
  • Novel therapeutic agents targeting PPARs are needed for effective diabetes management.

Purpose of the Study:

  • To evaluate the safety and efficacy of MK-767, a dual PPAR alpha and PPAR gamma agonist.
  • To investigate the potential of MK-767 as a treatment for diabetes mellitus.

Main Methods:

  • MK-767 is currently undergoing Phase III clinical trials in the United States.
  • Phase I trials are being conducted in Japan to assess safety and pharmacokinetics.
  • The development is a collaborative effort between Banyu, Kyorin, and Merck.

Related Experiment Videos

Main Results:

  • Data from ongoing trials will determine the efficacy and safety profile of MK-767.
  • Pharmacological activity is based on its agonist action on PPAR alpha and PPAR gamma.

Conclusions:

  • MK-767 represents a potential novel therapeutic strategy for diabetes.
  • Further clinical evaluation is required to establish its role in diabetes treatment.